AstraZeneca PLC (AZN) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Total Assets Chart for AstraZeneca PLC
AstraZeneca PLC (AZN) total assets for FY2025 were GBP 114.1B, a 9.6% change from FY2024. AstraZeneca PLC's total assets grew from GBP 6.1B in 1990 to GBP 114.1B in 2025 (1769.7% over 35 years). Total assets compound annual growth rate: 5-year CAGR of 11.3%, 10-year CAGR of 6.6%, 20-year CAGR of 7.9%.
Total Assets (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £216.51B
- Implied Share Price
- £139.60
- Enterprise Value
- £235.96B
- Revenue (TTM)
- £62.38B
- EBITDA
- £21.28B
- Profit Margin
- 17.68%
- Trailing P/E
- 27.98
- Forward P/E
- 16.31
- Price/Book (MRQ)
- 5.60
- Price/Sales (TTM)
- 3.47
- EV/EBITDA
- 14.91
- EV/Revenue
- 5.06
- Dividend Yield
- 2.47%
- Book Value
- £24.21
- Free Cash Flow (FY2025)
- £8.67B
- Free Cash Flow Yield
- 4.00%
Snapshot as of 31st October 2026 — not point-in-time controlled, may lag the live market by a few days.